Ralph Preiss

2.0k total citations · 1 hit paper
16 papers, 1.3k citations indexed

About

Ralph Preiss is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Ralph Preiss has authored 16 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 6 papers in Cardiology and Cardiovascular Medicine and 4 papers in Molecular Biology. Recurrent topics in Ralph Preiss's work include Pulmonary Hypertension Research and Treatments (12 papers), Heart Failure Treatment and Management (4 papers) and Cardiovascular Issues in Pregnancy (4 papers). Ralph Preiss is often cited by papers focused on Pulmonary Hypertension Research and Treatments (12 papers), Heart Failure Treatment and Management (4 papers) and Cardiovascular Issues in Pregnancy (4 papers). Ralph Preiss collaborates with scholars based in United States, Switzerland and Germany. Ralph Preiss's co-authors include Iréne Lang, Vallerie V. McLaughlin, Hossein Ardeschir Ghofrani, Nazzareno Galiè, Kelly Chin, Marius M. Hoeper, Victor F. Tapson, Seán Gaine, Olivier Sitbon and Gérald Simonneau and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Ralph Preiss

16 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selexipag for the Treatment of Pulmonary Arterial Hypertension

2015 706 citations Olivier Sitbon, Richard N. Channick et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ralph Preiss United States	11	992	664	225	160	151	16	1.3k
Andrei Seferian France	18	1.1k 1.1×	411 0.6×	272 1.2×	260 1.6×	89 0.6×	45	1.5k
Shelley Shapiro United States	13	1.4k 1.4×	781 1.2×	100 0.4×	234 1.5×	174 1.2×	29	1.5k
Vasile Foris Austria	18	786 0.8×	341 0.5×	162 0.7×	89 0.6×	96 0.6×	54	1.1k
Gérald Simonneau France	5	1.5k 1.5×	853 1.3×	169 0.8×	459 2.9×	92 0.6×	5	1.6k
Carmen Treacy United Kingdom	10	1.2k 1.2×	621 0.9×	168 0.7×	199 1.2×	18 0.1×	17	1.3k
Franck‐Olivier Le Brun United States	10	1.1k 1.1×	775 1.2×	70 0.3×	215 1.3×	237 1.6×	16	1.3k
Marina D. Kaymakcalan United States	15	374 0.4×	225 0.3×	261 1.2×	98 0.6×	52 0.3×	32	912
Henrik ten Freyhaus Germany	17	383 0.4×	295 0.4×	218 1.0×	56 0.3×	59 0.4×	45	787
Mathieu C. Tamby France	18	492 0.5×	78 0.1×	169 0.8×	85 0.5×	332 2.2×	24	972
Charles Kuzma United States	11	261 0.3×	330 0.5×	168 0.7×	53 0.3×	139 0.9×	20	1.3k

Countries citing papers authored by Ralph Preiss

Since Specialization

Citations

This map shows the geographic impact of Ralph Preiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph Preiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph Preiss more than expected).

Fields of papers citing papers by Ralph Preiss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph Preiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph Preiss. The network helps show where Ralph Preiss may publish in the future.

Co-authorship network of co-authors of Ralph Preiss

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph Preiss. A scholar is included among the top collaborators of Ralph Preiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph Preiss. Ralph Preiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Waller, Edmund K., Mitchell E. Horwitz, Sarah Anand, et al.. (2024). MODULAATE (Part 1): An Open-Label, Dose-Finding Phase 2 Evaluation of Alpha-1 Antitrypsin for the Prevention of Graft-Versus-Host Disease in Patients Receiving Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 30(2). S261–S261. 2 indexed citations

Gaine, Seán, Olivier Sitbon, Richard N. Channick, et al.. (2021). Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. CHEST Journal. 160(1). 277–286. 22 indexed citations

Sitbon, Olivier, Kelly Chin, Lilla Di Scala, et al.. (2020). Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. The Journal of Heart and Lung Transplantation. 39(4). 300–309. 43 indexed citations

Beghetti, Maurice, Richard N. Channick, Kelly Chin, et al.. (2019). Selexipag Treatment for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease After Defect Correction: Insights from the Randomised Controlled Griphon Study. European Journal of Heart Failure. 21(3). 352–359. 37 indexed citations

Chin, Kelly, Lewis J. Rubin, Richard N. Channick, et al.. (2019). Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation. 139(21). 2440–2450. 57 indexed citations

Coghlan, Gerry, Richard N. Channick, Kelly Chin, et al.. (2018). Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs. 18(1). 37–47. 63 indexed citations

Gaine, Seán, Kelly Chin, Gerry Coghlan, et al.. (2017). Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal. 50(2). 1602493–1602493. 91 indexed citations

Preston, Ioana R., Richard N. Channick, Kelly Chin, et al.. (2017). Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. The Journal of Heart and Lung Transplantation. 37(3). 401–408. 18 indexed citations

Preston, Ioana R., Kelly Chin, Lilla Di Scala, et al.. (2016). Management of selexipag interruptions in the GRIPHON study. PA1870–PA1870. 2 indexed citations

10.

Sitbon, Olivier, Richard N. Channick, Kelly Chin, et al.. (2015). Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 373(26). 2522–2533. 706 indexed citations breakdown →

11.

McLaughlin, Vallerie V., Richard Channick, Kelly Chin, et al.. (2015). EFFECT OF SELEXIPAG ON MORBIDITY/MORTALITY IN PULMONARY ARTERIAL HYPERTENSION: RESULTS OF THE GRIPHON STUDY. Journal of the American College of Cardiology. 65(10). A1538–A1538. 26 indexed citations

12.

Channick, Richard N., Kelly Chin, Lilla Di Scala, et al.. (2015). Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH). CHEST Journal. 148(4). 961A–961A. 3 indexed citations

13.

Sitbon, Olivier, Richard N. Channick, Kelly Chin, et al.. (2015). Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results. OA4995–OA4995. 1 indexed citations

14.

Alten, Rieke, Juan J. Gómez‐Reino, Patrick Durez, et al.. (2011). Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskeletal Disorders. 12(1). 153–153. 114 indexed citations

15.

Koné‐Paut, Isabelle, Helen J. Lachmann, Jasmin Kuemmerle‐Deschner, et al.. (2011). Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Research & Therapy. 13(6). R202–R202. 103 indexed citations

16.

Oppenheimer, Federico, Shamkant Mulgaonkar, Ronald M. Ferguson, et al.. (2007). Impact of Long-Term Therapy With FTY720 or Mycophenolate Mofetil on Cardiac Conduction and Rhythm in Stable Adult Renal Transplant Patients. Transplantation. 83(5). 645–648. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact